Document ID: chunk:federal_register_of_legislation:F2024L00759:reg:9:p2
Version: federal_register_of_legislation:F2024L00759
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 7157–10564

onset or clinical worsening;
(15)      taking one of the following medications within the 3 months before clinical onset or clinical worsening:
(a)          5-fluorouracil (non-topical);
(b)          alemtuzumab;
(c)          amphotericin B;
(d)          anagrelide;
(e)          bevacizumab;
(f)           cisplatin;
(g)          clozapine;
(h)          cobimetinib;
(i)            cyclophosphamide;
(j)            dasatinib;
(k)          exogenous catecholamine;
(l)            ifosfamide;
(m)        imatinib;
(n)          interferon alpha;
(o)          isotretinoin or tretinoin;
(p)          lithium;
(q)          methylphenidate;
(r)           mitomycin C;
(s)           olanzapine;
(t)            osimertinib;
(u)          paclitaxel (when used in combination with doxorubicin);
(v)          sunitinib;
(w)        tacrolimus;
(x)          trabectedin;
(y)          trametinib;
(z)          trastuzumab; or
(aa)       zidovudine;
(16)      taking a medication that cannot be ceased or substituted in the long term and which is associated in the individual with the development/worsening of cardiomyopathy during medication therapy; and either:
(a)          the improvement of cardiomyopathy within days or weeks of discontinuing or tapering medication therapy; or
(b)          the redevelopment/worsening of cardiomyopathy on rechallenge with the same medication; and
where the medication was being taken within the 3 months before clinical onset or clinical worsening;
(17)      being treated with an anthracycline within the 25 years before clinical onset or clinical worsening;
Note: anthracycline is defined in the Schedule 1 - Dictionary.
(18)      taking chloroquine or hydroxychloroquine daily for at least the one year before clinical onset or clinical worsening;
(19)      for males only, consuming an average of at least 80 grams of alcohol per day for a continuous period of at least 5 years, before clinical onset or clinical worsening;
Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(20)      for females only, consuming an average of at least 40 grams of alcohol per day for a continuous period of at least 5 years, before clinical onset or clinical worsening;
Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(21)      using one of the following illicit drugs at the time of clinical onset or clinical worsening:
(a)          amphetamines or amphetamine derivatives, including 3, 4-methylenedioxymethamphetamine (Ecstasy);
(b)          anabolic-androgenic steroids; or
(c)          cocaine;
(22)      being poisoned with cobalt, as demonstrated by haematological or biochemical evidence, at the time of clinical onset or clinical worsening;
(23)      being in the last trimester of pregnancy or being within the six months immediately postpartum at the time of clinical onset or clinical worsening;
(24)      undertaking intense physical activity of at least 6 METs at the time of clinical worsening;
Note: MET is defined in the Schedule 1 - Dictionary.
(25)      being a prisoner of war of Japan before clinical onset;
(26)      experiencing a severe stressful event that causes an intense emotional or psychological response within the 30 days before the clinical onset or clinical worsening of takotsubo cardiomyopathy;
Note: